<DOC>
	<DOCNO>NCT01392469</DOCNO>
	<brief_summary>This study investigate effect QTI571 ( imatinib ) pharmacokinetics bosentan sildenafil steady state co-administered pulmonary arterial hypertension patient .</brief_summary>
	<brief_title>Pharmacokinetic Effects QTI571 Sildenafil Bosentan Pulmonary Arterial Hypertension Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Pulmonary arterial hypertension ( PAH ) patient WHO Diagnostic Group 1 , pulmonary vascular resistance &gt; 800 dyne•sec•cm5 , On stable dos bosentan sildenafil Other diagnosis PAH WHO Diagnostic Group 1 congenital large small unrepaired systemic pulmonary shunt , portal hypertension , HIV infection , glycogen storage disease , Gaucher 's disease , hereditary hemorrhagic teleangiectasia , hemoglobinopathy , myeloproliferative disorder , venoocclusive pulmonary disease Significant lung disease related PAH Significant cardiovascular system disorder , hematological system disorder , liver insufficiency Significant diseases organ system . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pulmonary arterial hypertension</keyword>
	<keyword>pulmonary vascular resistance</keyword>
	<keyword>imatinib</keyword>
	<keyword>bosentan</keyword>
	<keyword>sildenafil</keyword>
</DOC>